Investigational Site

Columbus, Ohio 43230

0 studies enrolling now · 13 studies all time

What they study most

Active Rheumatoid Arthritis, Alzheimer's Disease, Anemia in Incident Dialysis Patients, Augmented Renal Clearance (ARC), Bacterial Infection, Bacterial Infections, Bipolar Disorder, Infections, Low Back Pain, Onychomycosis of Toenails, Palmoplantar Pustulosis, Rheumatoid Arthritis

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis — Completed
• Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants — Completed
• Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail — Completed
• Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance — Completed
• Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder — Completed
• Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections — Completed
• Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections — Completed
• Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis — Completed
• Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus — Completed
• A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain — Completed
• Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain — Completed
• Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis — Completed
• A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early